Scientific Sessions 2024  /  Temporary and Durable Mechanical Circulatory Support in Heart Failure Management  /  Impact of Heart Failure Readmission in HeartMate 3 LVAD Recipients
Logo

American Heart Association

  95
  0

Final ID: MDP854

Impact of Heart Failure Readmission in HeartMate 3 LVAD Recipients

Abstract Body (Do not enter title and authors here):
Background: Despite the survival benefit of durable left ventricular assist device (LVAD) therapy in patients with advanced heart failure, hospital readmissions due to heart failure (HF) remain a significant morbidity and determinant of quality of life.

Objective: This study aimed to characterize patients with and without a HF readmission and determine its clinical impact following HeartMate 3 (HM3) LVAD implantation.

Methods/Approach: A single-center retrospective analysis was performed of patients who underwent HM3 LVAD implantation from January 1, 2015 to December 31, 2021. Patients with and without a HF readmission were compared based on 53 variables. Cox proportional hazard model was performed to investigate the association between HF readmission and survival.

Results: A total of 273 patients underwent HM3 implantation. The average implant age was 58 years, 75% were men, and 78% were Black patients. Of the 273 patients, 78 (29%) had a HF readmission and 58 (74%) occurred within the first year following implant. Predictors of a HF readmission include pre-implant diabetes mellitus (HR 1.96; 95% CI, 1.2-3.2; p=0.007), pre-implant body mass index (HR 1.05; 95% CI, 1.02-1.09; p<0.001) and post implant BUN (HR 1.02; 95% CI, 1-1.04; p=0.018). There was no significant difference in survival in patients with and without a HF readmission (multivariate-adjusted HR 1.44; 95% CI, 0.87-2.37; p=0.153; Figure) at long-term follow up (6 years).

Conclusion: Readmissions for HF remain an opportunity for improvement in the care of HM3 LVAD patients. However, a HF readmission was not associated with an increased risk of death. Addressing comorbid conditions and identifying strategies to optimize LVAD and HF management in this high-risk cohort warrant further exploration to improve clinical outcomes.
  • Tejada Frisancho, Flavia  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Balsara, Keki  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Sheikh, Farooq  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Lam, Phillip  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Li, Zhi  ( Georgetown University School of Medicine , Washington , District of Columbia , United States )
  • Shaban, Liza  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Kadakkal, Ajay  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Hockstein, Michael  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Gupta, Richa  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Glocker, Shawn  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Pinilla-vera, Miguel  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
  • Rodrigo, Maria  ( MedStar Washington Hospital Center , Washington DC , District of Columbia , United States )
    • Author Disclosures:
    Flavia Tejada Frisancho: DO NOT have relevant financial relationships | Keki Balsara: No Answer | Farooq Sheikh: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Research Funding (PI or named investigator):Alexion:Active (exists now) ; Research Funding (PI or named investigator):Akcea:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Consultant:Alnylam:Active (exists now) | Phillip Lam: No Answer | Zhi Li: DO NOT have relevant financial relationships | Liza Shaban: DO NOT have relevant financial relationships | Ajay Kadakkal: No Answer | Michael Hockstein: No Answer | Richa Gupta: DO have relevant financial relationships ; Speaker:CVRx:Active (exists now) | Shawn Glocker: No Answer | Miguel Pinilla-Vera: DO NOT have relevant financial relationships | Maria Rodrigo: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Temporary and Durable Mechanical Circulatory Support in Heart Failure Management

Sunday, 11/17/2024 , 09:30AM - 10:45AM

Moderated Digital Poster Session

More abstracts on this topic:
A Cardiac Targeting Peptide Linked to miRNA106a Targets and Suppresses Genes Known to Cause Heart Failure: Reversing Heart Failure at the Source

Lu Ming, Deng Claire, Taskintuna Kaan, Ahern Gerard, Yurko Ray, Islam Kazi, Zahid Maliha, Gallicano Ian

A New Analytical Approach for Noninvasive Reconstruction of the Entire Left Ventricular Pressure Waveform in Myocardial Ischemia and Infarction

Bilgi Coskun, Li Jiajun, Alavi Rashid, Dai Wangde, Matthews Ray, Kloner Robert, Pahlevan Niema

More abstracts from these authors:
Clinical outcomes in patients with early right ventricular failure during index admission after HeartMate 3 LVAD implantation

Tejada Frisancho Flavia, Molina Ezequiel, Balsara Keki, Sheikh Farooq, Lam Phillip, Li Zhi, Shaban Liza, Kadakkal Ajay, Gupta Richa, Pinilla Miguel, Hofmeyer Mark, Hockstein Michael, Rodrigo Maria

Utilization of Palliative Care for Patients Living with Long-Term (LT) LVAD Therapy

El Khoury Marc, Sheikh Farooq, Rao Anirudh, Creechan Patrick, Gupta Richa, Hockstein Michael, Avila-quintero Victor, Flores Jose, Balsara Keki, Anderson Kelley, Groninger Hunter

4143583_File000000.jpg
4143583_File000000.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available